文献速递肾小球疾病慢性肾脏病

伊普可泮抑制替代补体途径治疗C3肾小球病——APPEAR-C3G试验设计

Alternative Complement Pathway Inhibition With Iptacopan for the Treatment of C3 Glomerulopathy-Study Design of the APPEAR-C3G Trial.
PubMed 文献 · Kidney Int Rep · 2022-08-02

C3肾小球病(C3G)缺乏获批疗法,约50%患者在诊断后10年内进展至肾衰竭。APPEAR-C3G是一项随机、双盲、安慰剂对照III期研究,纳入68例活检确诊的C3G成人患者,评估口服B因子抑制剂伊普可泮的疗效与安全性。患者按1:1随机接受伊普可泮200 mg每日两次或安慰剂治疗6个月,随后所有患者开放标签接受伊普可泮200 mg每日两次治疗6个月。主要目的是评估伊普可泮对比安慰剂减少蛋白尿(24小时尿蛋白肌酐比值)的疗效。

要点

  • APPEAR-C3G为随机双盲安慰剂对照III期研究,纳入68例活检确诊C3G成人患者。
  • 患者随机接受伊普可泮200 mg每日两次或安慰剂治疗6个月,随后开放标签伊普可泮200 mg每日两次治疗6个月。
  • 主要终点为24小时尿蛋白肌酐比值(UPCR)的蛋白尿减少,关键次要终点包括eGFR、组织学疾病总活动度评分和疲劳。

核心结论

  • 本研究旨在证明伊普可泮抑制替代补体途径在C3G中的临床获益。

研究设计与样本

  • APPEAR-C3G(NCT04817618)是一项随机、双盲、安慰剂对照III期研究,纳入68例活检确诊的C3G成人患者。
  • 入组标准包括补体C3降低(<77 mg/dl)、蛋白尿≥1.0 g/g、估算肾小球滤过率(eGFR)≥30 ml/min per 1.73 m2。
  • 所有患者接受最大耐受剂量的血管紧张素转换酶抑制剂/血管紧张素受体拮抗剂和针对荚膜细菌的疫苗接种。
  • 排除任何器官移植、进行性新月体性肾小球肾炎、意义未明的单克隆丙种球蛋白病、或肾活检示间质纤维化/肾小管萎缩>50%的患者。
  • 患者按1:1随机接受伊普可泮200 mg每日两次或安慰剂治疗6个月,随后所有患者开放标签接受伊普可泮200 mg每日两次治疗6个月。

主要发现

  • 主要目的是评估伊普可泮对比安慰剂减少蛋白尿(24小时尿蛋白肌酐比值,UPCR)的疗效。
  • 关键次要终点将评估通过eGFR测量的肾功能、组织学疾病总活动度评分和疲劳。

关键数值与推荐

  • II期研究中,伊普可泮治疗分别与原生肾和移植肾C3G患者的蛋白尿减少和C3沉积评分降低相关。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Complement 3 glomerulopathy (C3G) is a rare kidney disease characterized by dysregulation of the alternative pathway (AP) of the complement system. About 50% of patients with C3G progress to kidney failure within 10 years of diagnosis. Currently, there are no approved therapeutic agents for C3G. Iptacopan is an oral, first-in-class, potent, and selective inhibitor of factor B, a key component of the AP. In a Phase II study, treatment with iptacopan was associated with a reduction in proteinuria and C3 deposit scores in C3G patients with native and transplanted kidneys, respectively. METHODS: APPEAR-C3G (NCT04817618) is a randomized, double-blind, and placebo-controlled Phase III study to evaluate the efficacy and safety of iptacopan in C3G patients, enrolling 68 adults with biopsy-confirmed C3G, reduced C3 (<77 mg/dl), proteinuria ≥1.0 g/g, and estimated glomerular filtration rate (eGFR) ≥30 ml/min per 1.73 m2. All patients will receive maximally tolerated angiotensin-converting enzyme inhibitor/angiotensin receptor blocker and vaccination against encapsulated bacteria. Patients with any organ transplantation, progressive crescentic glomerulonephritis (GN), monoclonal gammopathy of undetermined significance, or kidney biopsy with >50% interstitial fibrosis/tubular atrophy, will be excluded. Patients will be randomized 1:1 to receive either iptacopan 200 mg twice daily or placebo for 6 months, followed by open-label treatment with iptacopan 200 mg twice daily for all patients for 6 months. The primary objective is to evaluate the efficacy of iptacopan versus placebo on proteinuria reduction urine protein:creatinine ratio (UPCR) (24 h urine). Key secondary endpoints will assess kidney function measured by eGFR, histological disease total activity score, and fatigue. CONCLUSION: This study aims to demonstrate the clinical benefits of AP inhibition with iptacopan in C3G.

来源:Kidney Int Rep,查看原文。版权归原作者所有。

引用

  1. Bomback AS, Kavanagh D, Vivarelli M, et al. Alternative Complement Pathway Inhibition With Iptacopan for the Treatment of C3 Glomerulopathy-Study Design of the APPEAR-C3G Trial. Kidney Int Rep. 2022. PMID: 36217526. doi:10.1016/j.ekir.2022.07.004

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。